Core Viewpoint - The innovation drug sector in both A-shares and Hong Kong stocks experienced a significant drop on September 10, primarily due to external media reports regarding potential restrictions from the Trump administration on Chinese pharmaceuticals. However, the sector demonstrated resilience with many stocks recovering during the day, indicating long-term investment opportunities despite short-term volatility [1][2]. Group 1: Market Reaction and Resilience - On September 10, the innovation drug sector opened sharply lower but showed strong recovery, with ETFs rebounding significantly after initial declines. For instance, an innovation drug ETF initially dropped over 5.7% but closed down only 0.51% [2]. - The Hang Seng pharmaceutical sector exhibited notable gains, with many funds recovering from early losses of over 8% to close within 2% down [2]. Group 2: Interpretation of External News - Fund managers believe that the reported policy changes from the U.S. government regarding drug imports from China are not new and will not have substantial impacts on the sector. The trend of Business Development (BD) collaborations between multinational corporations (MNCs) and Chinese innovation drug companies is expected to continue [2][3]. - The collaboration between MNCs and Chinese innovation drug firms is seen as a norm, with Chinese assets remaining globally competitive despite political noise [3]. Group 3: Fundamental Validation of Innovation Drugs - The innovation drug market has shown signs of fundamental improvement, with several companies, including Hengrui Medicine and BeiGene, expected to achieve revenue and profit growth in the first half of 2025. A report indicated that 39 Hong Kong innovation drug companies had a total revenue of 152.06 billion yuan (approximately $22.4 billion) in the first half of 2025, marking a 7.66% year-on-year increase [4]. - The underlying reasons for the current market trend include the recognition of efficient R&D and clinical innovation capabilities, which are expected to drive further market growth [4][5]. Group 4: Investment Outlook and Strategies - The investment outlook for innovation drugs is positive, with three main areas of focus: the profitability of Chinese innovation drug companies, the potential of AI in healthcare, and the valuation of leading companies in non-innovation drug sectors [5]. - Fund managers suggest that despite the recent market fluctuations, the long-term trend for innovation drugs remains upward, with a shift towards larger, more established companies that have already launched products and demonstrated performance [6]. Group 5: Short-term Risks and Opportunities - While the innovation drug sector shows resilience, there are warnings about potential short-term volatility due to market sentiment and policy uncertainties. Fund managers advise caution and suggest that recent price corrections may present good buying opportunities [6]. - Historical trends indicate that market reactions to sudden policy changes often create favorable conditions for investment, suggesting that current fluctuations could be leveraged for strategic positioning [6].

Summary of Key Points Core Viewpoint - The report highlights the short-selling ratios and amounts for various stocks, indicating significant bearish sentiment in the market, particularly for New World Development, Li Ning, and BYD, which have the highest short-selling ratios [1][2]. Short-Selling Ratios - New World Development and Li Ning both have a short-selling ratio of 100.00%, indicating complete bearish positions [2]. - BYD has a short-selling ratio of 91.94%, suggesting strong negative sentiment towards the stock [2]. Short-Selling Amounts - Alibaba leads in short-selling amount with 7.482 billion, followed by China Pacific Insurance at 1.943 billion and Meituan at 1.420 billion [2]. - Tencent Holdings and CSPC Pharmaceutical also feature in the top five for short-selling amounts, with 1.006 billion and 0.887 billion respectively [2]. Deviation Values - China Ping An has the highest deviation value at 45.98%, indicating a significant difference between its current short-selling ratio and its average over the past 30 days [2]. - China Pacific Insurance and Lai Kai Pharmaceutical follow with deviation values of 44.30% and 39.82% respectively, suggesting notable shifts in market sentiment [2].

Summary of Key Points from Conference Call Records Industry Overview - The global pharmaceutical industry is facing a "patent cliff," with over 40% of revenues affected for many multinational companies, creating opportunities for Chinese innovative drug companies to introduce their assets [1][3][4] - The Chinese innovative drug sector is experiencing a diverse globalization path, including overseas expansion, business development, and joint ventures, with significant collaboration with regions like Europe, Southeast Asia, and the Middle East [1][5] Company Performance - **Hengrui Medicine**: Achieved a revenue growth of 15.88% and a net profit growth of 29.67% in the first half of the year, with expectations for further performance improvement in the second half [1][7] - **Kangfang Biotech**: Reported a revenue increase of 49.20% in the first half of the year, with promising data from its API12 presented at WCLC and ongoing global clinical trials for AK104 [1][8] Market Dynamics - The innovative drug sector showed healthy performance in the first half of the year, with significant contributions from products entering the medical insurance list, enhancing profit margins for companies like Kangfang Biotech, Hengrui Medicine, and others [1][6] - The domestic CRO (Contract Research Organization) industry is entering a new phase after adjustments, with a recovery in overseas demand and a clear trend of Chinese innovative drugs moving into late-stage clinical trials [3][10][11] Future Trends and Drivers - The core driving force for Chinese innovative drugs going global is their breakthrough global competitiveness, particularly in next-generation immunotherapy and antibody-drug conjugates (ADCs) [2][12] - The domestic CRO industry is expected to benefit from sustained global innovation demand, increased R&D spending, and the internationalization of Chinese innovative drugs [12] Geopolitical Impact - Geopolitical factors have influenced the Chinese CRO industry, with concerns arising from U.S. regulations, but these have been alleviated over time as companies enhance their core capabilities and expand overseas [13] Notable Companies and Products - **Innovative Products**: - **Sinda's PD-L1 monoclonal antibody**: Demonstrated promising survival data for patients with solid tumors, indicating a broad international market potential [19] - **Gree Pharmaceutical's GLP-1 drugs**: Showed favorable clinical data with significant market potential due to expected weight loss effects [20][21] - **Leading CDMO Companies**: Companies like WuXi AppTec reported a 21% revenue growth and a 102% increase in net profit, benefiting from the ADC industry and overseas expansion [3][14] Conclusion - The Chinese innovative drug sector is poised for growth, driven by strong performance metrics, a favorable global market environment, and strategic international collaborations. The ongoing developments in clinical trials and product launches are expected to further enhance the competitive landscape for these companies [1][9][22][23][24]

Market Overview - On September 11, the Hang Seng Index fell by 0.43%, closing at 26,086.32 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 18.989 billion [1][3] - The total trading volume for the Stock Connect on September 11 was HKD 172.214 billion, with a net purchase of HKD 18.989 billion [1] Stock Performance - In the Shanghai Stock Connect, the total trading volume was HKD 103.737 billion, with a net purchase of HKD 8.073 billion [1] - In the Shenzhen Stock Connect, the total trading volume was HKD 68.477 billion, with a net purchase of HKD 10.916 billion [1] Active Stocks - The most actively traded stock in the Shanghai Stock Connect was Alibaba-W, with a trading volume of HKD 80.75 billion and a net purchase of HKD 29.46 billion, closing up by 0.35% [1][2] - Meituan-W had the highest net sell amount of HKD 9.36 billion, closing down by 5.06% [1][2] - In the Shenzhen Stock Connect, Alibaba-W also led with a trading volume of HKD 43.575 billion and a net purchase of HKD 7.835 billion [2] - The top net purchase stock was Innovent Biologics, with a net purchase of HKD 0.847 billion, despite closing down by 2.51% [2] Summary of Key Stocks | Stock Code | Stock Name | Trading Volume (HKD million) | Net Purchase (HKD million) | Daily Change (%) | |------------|------------------|------------------------------|----------------------------|-------------------| | 09988 | Alibaba-W | 807.48 | 294.62 | 0.35 | | 03690 | Meituan-W | 618.38 | -93.59 | -5.06 | | 00981 | SMIC | 491.04 | 41.75 | 4.97 | | 01801 | Innovent Biologics| 253.79 | 84.73 | -2.51 | | 00700 | Tencent Holdings | 263.33 | -92.26 | -0.63 | [2]

Market Overview - On September 11, the Hang Seng Index fell by 0.43% with a total southbound trading volume of HKD 172.21 billion, including buy transactions of HKD 95.60 billion and sell transactions of HKD 76.61 billion, resulting in a net buy of HKD 18.99 billion [1] Southbound Trading Activity - The southbound trading through Stock Connect (Shenzhen) had a total trading volume of HKD 68.48 billion, with buy transactions of HKD 39.70 billion and sell transactions of HKD 28.78 billion, leading to a net buy of HKD 10.92 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading volume of HKD 103.74 billion, with buy transactions of HKD 55.91 billion and sell transactions of HKD 47.83 billion, resulting in a net buy of HKD 8.07 billion [1] Active Stocks - Alibaba-W was the most actively traded stock with a total trading volume of HKD 124.32 billion and a net buy of HKD 37.30 billion, closing with a price increase of 0.35% [1][2] - Other notable stocks included Meituan-W and SMIC, with trading volumes of HKD 84.52 billion and HKD 80.43 billion, respectively [1] - Tencent Holdings had the highest net sell amount of HKD 11.51 billion, closing down by 0.63% [1][2] Continuous Net Buying and Selling - Alibaba-W and SMIC were the only two stocks with continuous net buying for more than three days, with Alibaba-W having a total net buy of HKD 371.43 billion over 15 days and SMIC with HKD 15.76 billion over 3 days [2] - Stocks with continuous net selling included Kangfang Biotech, Tencent Holdings, and Meituan-W, with total net sell amounts of HKD 17.48 billion, HKD 14.61 billion, and HKD 10.28 billion, respectively [2]

Group 1: Investment Trends - Significant net purchases were observed in Alibaba-W (37.3 billion), Innovent Biologics (9.56 billion), and SMIC (9.32 billion) among others, while Tencent Holdings saw a net sell-off of 11.51 billion [1][4] - Southbound funds have continuously net bought Alibaba for 15 days, totaling 371.4389 billion HKD, and have net sold Tencent for 3 days, totaling 14.6076 billion HKD [4] Group 2: Company Developments - Alibaba's "Gaode Street Ranking" launched on September 10, attracting over 40 million users, indicating a strategic move to enhance user engagement and monetization through local services [6] - Reports suggest that the Trump administration is drafting an executive order to impose strict restrictions on Chinese pharmaceuticals, which may impact companies like Innovent Biologics and BeiGene [7] - SMIC is benefiting from high demand in the semiconductor industry driven by AI computing needs and accelerated domestic substitution in equipment and materials [7] Group 3: Market Reactions - UBS reports that the recent price correction of Pop Mart is creating buying opportunities ahead of key product launches and the Christmas sales season, maintaining a "Buy" rating with a target price of 432 HKD [7] - Tencent has repurchased 874,000 shares for 5.5 billion HKD and is considering issuing offshore RMB bonds, marking its first bond issuance since April 2021 [8]

Core Viewpoint - The AH innovative drug sector experienced significant volatility due to external negative news, but ultimately managed to stabilize after initial panic selling [1][4]. Market Performance - The A-share innovative drug ETF (562050) initially dropped over 4%, while the Hong Kong Stock Connect innovative drug ETF (520880) saw a decline of nearly 8% at the start [1]. - By the end of the trading day, the A-share ETF closed down 0.7%, and the Hong Kong ETF finished down 1.82%, with an intraday fluctuation of 6.67% and a trading volume of 928 million yuan, an increase of over 88% compared to the previous day [1]. Stock Performance - Major stocks in the innovative drug sector faced declines, including: - Kangfang Biotech (9926) down 4.34% with a market cap of 117.6 billion yuan [2] - Innovent Biologics (1801) down 2.51% with a market cap of 166.3 billion yuan [2] - Stone Pharmaceutical (1093) down 7.50% with a market cap of 116.6 billion yuan [2] - Conversely, smaller-cap stocks like Yaojie Ankang-B (2617) surged over 30%, and other stocks like InnoCare Pharma-B (9606) and Rongchang Biotech (1801) rose by 16.86% and 10.16%, respectively [4]. External Factors - Reports indicated that the Trump administration might draft legislation imposing strict restrictions and reviews on Chinese pharmaceuticals, raising concerns about potential disruptions to Chinese innovative drug business development [2][4]. Market Sentiment and Future Outlook - Fund manager Feng Chen stated that the likelihood of the U.S. banning Chinese innovative drug business development is minimal, as the proposed legislation is not a priority [5]. - The innovative drug sector is expected to see significant divergence in market sentiment, with potential buying opportunities for high-quality innovative drug stocks following the recent market adjustments [5]. - The Hong Kong Stock Connect innovative drug ETF (520880) has seen substantial inflows, with a total of 280 million yuan over the past week and a net inflow rate exceeding 187% over the last 60 days [5]. Index Adjustments - The Hong Kong Stock Connect innovative drug ETF (520880) underwent a "purification" adjustment on September 8, removing CXO stocks to better reflect the innovative drug industry's development trends [7]. - Prior to this adjustment, the index had achieved a year-to-date increase of 119.75%, outperforming other innovative drug indices [7].

Core Insights - On September 11, 2025, Alibaba-W (09988), Meituan-W (03690), and SMIC (00981) were the top three stocks by trading volume in the southbound trading of the Shanghai-Hong Kong Stock Connect, with trading amounts of 8.075 billion, 6.184 billion, and 4.910 billion respectively [1] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Innovent Biologics (01801) led the trading volume, with amounts of 4.357 billion, 3.132 billion, and 2.538 billion respectively [1] Southbound Trading Highlights - **Shanghai-Hong Kong Stock Connect:** - Alibaba-W (09988): Trading amount of 8.075 billion, net buying of 2.946 billion - Meituan-W (03690): Trading amount of 6.184 billion, net selling of 0.936 billion - SMIC (00981): Trading amount of 4.910 billion, net buying of 0.417 billion - Other notable companies include Kangfang Biologics (09926) with a trading amount of 2.797 billion and net selling of 0.755 billion, and Tencent Holdings (00700) with a trading amount of 2.633 billion and net selling of 0.923 billion [2] - **Shenzhen-Hong Kong Stock Connect:** - Alibaba-W (09988): Trading amount of 4.357 billion, net buying of 0.784 billion - SMIC (00981): Trading amount of 3.132 billion, net buying of 0.515 billion - Innovent Biologics (01801): Trading amount of 2.538 billion, net buying of 0.847 billion - Other significant companies include Kangfang Biologics (09926) with a trading amount of 2.418 billion and net buying of 0.365 billion, and Meituan-W (03690) with a trading amount of 2.268 billion and net buying of 0.839 billion [2]

格隆汇9月11日｜南下资金今日净买入港股189.89亿港元。其中： | | 沪股通 | | | | | --- | --- | --- | --- | --- | | 名称 | 涨跌幅 | 净买入额(亿) | 成交额 | 名称 | | 阿里巴巴-W | 0.4% | 29.46 | 80.75 Z | 阿里巴巴-W | | 美团-W | -5.1% | -9.36 | 61.84 ( | 中芯国际 | | 中芯国际 | 5.0% | 4.17 | 49.10亿 | 信达生物 | | 康方生物 | -4.3% | -7.55 | 27.97 L | 康方生物 | | 腾讯控股 | -0.6% | -9.23 | 26.33 Z | 美团-W | | 药明生物 | 4.3% | 3.39 | 21.01亿 | 石药集团 | | 小米集团-W | -0.6% | 0.44 | 19.98 Z | 腾讯控股 | | 信达生物 | -2.5% | 1.10 | 19.04亿 | 百济神州 | | 长飞光纤光缆 | 11.8% | -0.57 | 18.94 Z | 三生制药 | | 泡泡玛特 | -0.7% | 4.8 ...

9月11日，港股创新药剧烈调整，翰森制药、石药集团、百济神州、中国生物制药、康方生物等千亿市 值龙头齐挫，多股跌超6%。 创新药纯度100%的港股通创新药ETF（520880）跳空低开后一度跌逾7%，午后低位震荡，尾盘发力回 升，场内收跌1．82%，全天成交超9．28亿元，环比激增超88%。 什么原因？消息面上，据外媒报道，特朗普政府可能草拟法案，对中国药品实施严厉的限制和审查措 施。市场担心中国创新药BD被打断，行情波动加大。 如何看待？港股通创新药ETF（520880）基金经理丰晨成火线解读： 1、矛头为何对准中国创新药BD？ 结合公开信息，该法案当前尚在起草阶段，白宫明确表示"不在优先事项"。事件本质是美国生物医药产 业在早期研发和效率上开始落后中国，美国生物医药指数今年以来大幅跑输中国生物医药指数，引发美 国早期投资人的不满和保守派人士的担忧。 2、传言会否成真？ 美国禁止中国创新药BD基本不可实现。 首先，这直接挑战川普阵营的基本盘和支持者，以及美国大药企MNC的根本利益。美国制药业龙头辉 瑞就明确表示，限制中国创新药将使得MNC错失获得最好的研发分子并进一步落后研发进度； 其次，如果失去中国的快速 ...